Drug Clinical Trials List

Display 341 - 350 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis” LUCENT 2	Eli Lilly	Ongoing	Mirikizumab	3	I6T-MC-AMBG	KFSH-D
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 1	Eli Lilly	Ongoing	Mirikizumab	3	I6T-MC-AMAN	KFSH-D
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Novartis	Ongoing	ABL001 (asciminib)	3	CABL001A2301	KFSH&RC-R
"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3"	Eli Lilly	Completed	Mirikizumab	3	I6T-MC-AMAP	King Fahad Specialist Hospital (Dammam)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease	Celgene	Ongoing	Ozanimod HCl	3	RPC01-3204	KAUH-J
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus"	MSD	Ongoing	Ertugliflozin	3	MK-8835-059-00	KSH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial	Celgene	Completed	Luspatercept (ACE 536)	3	ACE-536-B-THAL-001	KKUH
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.	Eli Lilly	Terminated	Prasugrel	3	H7T-MC-TADO	KAUH-J
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE	Pfizer	Completed	PF-06651600	2a	B7981007	NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah)
"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease "	Janssen-Cilag International NV	Ongoing	Guselkumab	2	CNTO1959CRD3001	KAMC